Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02997228
Recruitment Status : Recruiting
First Posted : December 20, 2016
Last Update Posted : November 13, 2019
Sponsor:
Collaborator:
NRG Oncology
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Condition or disease Intervention/treatment Phase
Colorectal Adenocarcinoma Stage IV Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Drug: Atezolizumab Biological: Bevacizumab Drug: Fluorouracil Drug: Leucovorin Calcium Drug: Oxaliplatin Other: Quality-of-Life Assessment Other: Questionnaire Administration Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 347 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Actual Study Start Date : November 7, 2017
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : April 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Arm I (bevacizumab, mFOLFOX6)
Patients receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Cycles of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Biological: Bevacizumab
Given IV
Other Names:
  • Anti-VEGF
  • Anti-VEGF Humanized Monoclonal Antibody
  • Anti-VEGF rhuMAb
  • Avastin
  • Bevacizumab awwb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab Biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab Biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • BP102
  • BP102 Biosimilar
  • HD204
  • Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer
  • Recombinant Humanized Anti-VEGF Monoclonal Antibody
  • rhuMab-VEGF
  • SCT501

Drug: Fluorouracil
Given IV
Other Names:
  • 5 Fluorouracil
  • 5 Fluorouracilum
  • 5 FU
  • 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
  • 5-Fluorouracil
  • 5-Fluracil
  • 5-FU
  • 5FU
  • AccuSite
  • Carac
  • Fluoro Uracil
  • Fluouracil
  • Flurablastin
  • Fluracedyl
  • Fluracil
  • Fluril
  • Fluroblastin
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757

Drug: Leucovorin Calcium
Given IV
Other Names:
  • Adinepar
  • Calcifolin
  • Calcium (6S)-Folinate
  • Calcium Folinate
  • Calcium Leucovorin
  • Calfolex
  • Calinat
  • Cehafolin
  • Citofolin
  • Citrec
  • citrovorum factor
  • Cromatonbic Folinico
  • Dalisol
  • Disintox
  • Divical
  • Ecofol
  • Emovis
  • Factor, Citrovorum
  • Flynoken A
  • Folaren
  • Folaxin
  • FOLI-cell
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Folinate Calcium
  • folinic acid
  • Folinic Acid Calcium Salt Pentahydrate
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leucosar
  • leucovorin
  • Rescufolin
  • Rescuvolin
  • Tonofolin
  • Wellcovorin

Drug: Oxaliplatin
Given IV
Other Names:
  • 1-OHP
  • Ai Heng
  • Aiheng
  • Dacotin
  • Dacplat
  • Diaminocyclohexane Oxalatoplatinum
  • Eloxatin
  • Eloxatine
  • JM-83
  • Oxalatoplatin
  • Oxalatoplatinum
  • RP 54780
  • RP-54780
  • SR-96669

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm II (atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Atezolizumab
Given IV
Other Names:
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL3280A
  • MPDL328OA
  • RG7446
  • RO5541267
  • Tecentriq

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm III (atezolizumab, bevacizumab, mFOLFOX6)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Cycles of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Atezolizumab
Given IV
Other Names:
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL3280A
  • MPDL328OA
  • RG7446
  • RO5541267
  • Tecentriq

Biological: Bevacizumab
Given IV
Other Names:
  • Anti-VEGF
  • Anti-VEGF Humanized Monoclonal Antibody
  • Anti-VEGF rhuMAb
  • Avastin
  • Bevacizumab awwb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab Biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab Biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • BP102
  • BP102 Biosimilar
  • HD204
  • Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer
  • Recombinant Humanized Anti-VEGF Monoclonal Antibody
  • rhuMab-VEGF
  • SCT501

Drug: Fluorouracil
Given IV
Other Names:
  • 5 Fluorouracil
  • 5 Fluorouracilum
  • 5 FU
  • 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
  • 5-Fluorouracil
  • 5-Fluracil
  • 5-FU
  • 5FU
  • AccuSite
  • Carac
  • Fluoro Uracil
  • Fluouracil
  • Flurablastin
  • Fluracedyl
  • Fluracil
  • Fluril
  • Fluroblastin
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757

Drug: Leucovorin Calcium
Given IV
Other Names:
  • Adinepar
  • Calcifolin
  • Calcium (6S)-Folinate
  • Calcium Folinate
  • Calcium Leucovorin
  • Calfolex
  • Calinat
  • Cehafolin
  • Citofolin
  • Citrec
  • citrovorum factor
  • Cromatonbic Folinico
  • Dalisol
  • Disintox
  • Divical
  • Ecofol
  • Emovis
  • Factor, Citrovorum
  • Flynoken A
  • Folaren
  • Folaxin
  • FOLI-cell
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Folinate Calcium
  • folinic acid
  • Folinic Acid Calcium Salt Pentahydrate
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leucosar
  • leucovorin
  • Rescufolin
  • Rescuvolin
  • Tonofolin
  • Wellcovorin

Drug: Oxaliplatin
Given IV
Other Names:
  • 1-OHP
  • Ai Heng
  • Aiheng
  • Dacotin
  • Dacplat
  • Diaminocyclohexane Oxalatoplatinum
  • Eloxatin
  • Eloxatine
  • JM-83
  • Oxalatoplatin
  • Oxalatoplatinum
  • RP 54780
  • RP-54780
  • SR-96669

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years ]
    The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status, metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier.


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: The time from randomization to death from any cause, assessed up to 5 years ]
    Will be analyzed using the stratified log rank test. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals.

  2. Objective response rate (ORR) (complete response [CR] or partial response [PR]) [ Time Frame: Up to 5 years ]
    Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo). Observed proportions along with confidence intervals will be presented by treatment.

  3. Incidence of adverse events [ Time Frame: Up to 30 days after last course ]
    Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

  4. Surgical conversion rate [ Time Frame: Up to 5 years ]
    Defined as the proportion of patients that have surgery with curative intent. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo). Observed proportions along with confidence intervals will be presented by treatment.

  5. Disease control rate (CR + PR + stable disease [SD]) [ Time Frame: At 12 months ]
    Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo). Observed proportions along with confidence intervals will be presented by treatment.

  6. Duration of overall response (CR or PR) [ Time Frame: From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years ]
    Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals.

  7. PFS [ Time Frame: From randomization until first progression by retrospective central independent scan review or death from any cause, assessed up to 5 years ]

Other Outcome Measures:
  1. Severity of fatigue [ Time Frame: At 16 weeks ]
    Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-Bev) and the atezolizumab monotherapy arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered.

  2. Physical functioning [ Time Frame: At 16 weeks ]
    Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the atezolizumab monotherapy arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered.

  3. Severity and frequency of quality of life (QOL) and patient-reported outcomes (PRO) [ Time Frame: Up to 5 years ]
    Assessed using the PROMIS fatigue, EORTC QLQ-C30, and PRO-CTCAE measures. The corresponding item (PRO-CTCAE severity, PRO-CTCAE frequency, or QOL scale) will be compared between the control arm (Chemo-Bev) and each experimental arm in turn (atezolizumab monotherapy and Chemo-Bev plus atezolizumab combination therapy) using a mixed regression model for repeated measures with the response being ordinal for the PRO-CTCAE items and linear for QOL scales. The model will also include the corresponding baseline measurement, time, and stratification variables. Presence of treatment-by-time interaction will be investigated for each model. Each comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered.

  4. Health utility scores [ Time Frame: Up to 5 years ]
    Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire.

  5. Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G) [ Time Frame: Up to 5 years ]
  6. Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy [ Time Frame: Up to 5 years ]
  7. Efficacy dependent on the number of somatic mutations [ Time Frame: Up to 5 years ]
  8. Efficacy in tumors with MLH1 silencing [ Time Frame: Up to 5 years ]
  9. Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations [ Time Frame: Baseline up to 5 years ]
  10. Development of progression or relapse to treatment in cfDNA [ Time Frame: Up to 5 years ]
  11. Changes in T-cell repertoire diversity as a predictive biomarker of efficacy [ Time Frame: Baseline up to 5 years ]
  12. PFS of patients with high levels of diversity [ Time Frame: Up to 5 years ]
    Compared to patients with low levels of diversity.

  13. Change in T-cell diversity [ Time Frame: Baseline to first restaging between immunotherapy arms and the standard of care arm ]
  14. Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected [ Time Frame: Baseline up to 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer
  • Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; Note: microsatellite instability high (MSI-H) diagnosed by microsatellite instability (MSI) testing (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) is not eligible unless dMMR is confirmed by CLIA-certified immunohistochemical (IHC) assay with a panel of all four IHC markers including MLH1, MSH2, PMS2 and MSH6
  • An adequate amount of archived tumor tissue, either from primary colorectal cancer site or metastatic lesions, for central confirmation of dMMR status:

    • Either whole or part of the formalin-fixed paraffin-embedded (FFPE) block containing tumor tissue; or
    • At least 9 unstained slides containing tumor sections
  • Documentation by positron emission tomography(PET)/computed tomography (CT) scan, CT scan, or magnetic resonance imaging (MRI) that the patient has untreated measurable metastatic disease per RECIST 1.1
  • No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass
  • Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)
  • Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)
  • Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)
  • Total bilirubin must be =< 1.5 x ULN (upper limit of normal) for the lab unless the patient has a bilirubin elevation > 1.5 x ULN to 3 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin (obtained within 28 days prior randomization); and
  • Alkaline phosphatase must be =< 2.5 x ULN for the lab with the following exception: patients with documented liver metastases or bone involvement - alkaline phosphatase must be =< 5 x ULN (obtained within 28 days prior randomization); and
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)
  • Serum creatinine =< 1.5 x ULN for the lab or measured or calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)
  • A urine sample tested for proteinuria by the dipstick method must indicate 0 -1+ protein; if dipstick reading is >= 2+, a 24-hour urine specimen must demonstrate < 1.0 g of protein per 24 hours
  • International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history
  • Pregnancy test done within 14 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab and/or mFOLFOX6/bevacizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; men with female partners of child-bearing potential must agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after the last dose of bevacizumab and 6 months after the last dose of mFOLFOX6

Exclusion Criteria:

  • Patients with central nervous system (CNS) metastases are excluded, with the following exceptions:

    • Patients with asymptomatic untreated CNS metastases may be enrolled, provided all eligibility criteria are met, as well as the following:

      • Evaluable or measurable disease outside the CNS
      • No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm)
      • No history of intracranial hemorrhage or spinal cord hemorrhage
      • No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted.
      • No neurosurgical resection or brain biopsy within 28 days prior to randomization
    • Patients with asymptomatic treated CNS metastases may be enrolled, provided all eligibility criteria are met, as well as the following:

      • Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study
      • No stereotactic radiation or whole-brain radiation within 28 days prior to randomization
      • Screening CNS radiographic study >= 28 days from completion of radiotherapy and >= 14 days from discontinuation of corticosteroids
  • Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
  • Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP 90 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria
  • Any of the following cardiac conditions:

    • Documented New York Heart Association (NYHA) class III or IV congestive heart failure
    • Myocardial infarction within 6 months prior to randomization
    • Unstable angina within 6 months prior to randomization
    • Symptomatic arrhythmia
  • Serious or non-healing wound, skin ulcer, or bone fracture
  • History of transient ischemic attack (TIA), cerebrovascular accident (CVA), gastrointestinal (GI) perforation or arterial thrombotic event within 6 months prior to randomization or symptomatic peripheral ischemia
  • Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin
  • Known DPD (dihydro pyrimidine dehydrogenase) deficiency
  • Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0) in patients with no prior oxaliplatin therapy
  • Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization
  • Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:

    • Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
    • No history of severe immune-related adverse effects (CTCAE Grade 3 and 4) from anti-CTLA-4
  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier are excluded; however, the following therapies are allowed:

    • Hormone-replacement therapy or oral contraception
    • Herbal therapy > 7 days prior to randomization (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to randomization)
    • Palliative radiotherapy for bone metastases > 14 days prior to randomization
  • Treatment with systemic immunostimulatory medications (including, but not limited to interferon [IFN]-alpha or interleukin [IL]-2 within 42 days prior to randomization
  • Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,

    • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
    • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
  • Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
  • Patients requiring treatment with a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor (e.g., denosumab) who cannot discontinue it before treatment with atezolizumab
  • Treatment with any other investigational agent within 4 weeks prior to randomization
  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,

    • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible
    • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
  • History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
    • Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
    • Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

      • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
      • Rash must cover less than 10% of body surface area (BSA)
      • Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
      • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Patients with known active tuberculosis (TB) are excluded
  • Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
  • Signs or symptoms of infection within 14 days prior to randomization
  • Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
  • Administration of a live, attenuated vaccine within 28 days prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab; Note: influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 28 days prior to randomization or at any time during the study
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 14 days prior to randomization according to institutional standards for women of childbearing potential)
  • Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

    • A stable regimen of highly active anti-retroviral therapy (HAART); and
    • No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and
    • A CD4 count above 250 cells/uL and an undetectable HIV viral load on standard PCR-based tests
  • Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02997228


  Hide Study Locations
Locations
Layout table for location information
United States, Arkansas
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Recruiting
Jonesboro, Arkansas, United States, 72401
Contact: Site Public Contact    870-936-7067    Dawn.Smith@BMHCC.org   
Principal Investigator: Shailesh R. Satpute         
United States, California
Kaiser Permanente-Anaheim Recruiting
Anaheim, California, United States, 92806
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente-Baldwin Park Recruiting
Baldwin Park, California, United States, 91706
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente-Bellflower Recruiting
Bellflower, California, United States, 90706
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Alta Bates Summit Medical Center-Herrick Campus Recruiting
Berkeley, California, United States, 94704
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Kristie A. Bobolis         
John Muir Medical Center-Concord Campus Active, not recruiting
Concord, California, United States, 94520
Kaiser Permanente-Fontana Recruiting
Fontana, California, United States, 92335
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente - Harbor City Recruiting
Harbor City, California, United States, 90710
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente-Irvine Recruiting
Irvine, California, United States, 92618
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente Los Angeles Medical Center Recruiting
Los Angeles, California, United States, 90027
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente-Cadillac Recruiting
Los Angeles, California, United States, 90034
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Fremont - Rideout Cancer Center Recruiting
Marysville, California, United States, 95901
Contact: Site Public Contact    530-749-4400      
Principal Investigator: May T. Cho         
Saint Joseph Hospital - Orange Recruiting
Orange, California, United States, 92868
Contact: Site Public Contact    714-734-6220      
Principal Investigator: Timothy E. Byun         
UC Irvine Health/Chao Family Comprehensive Cancer Center Recruiting
Orange, California, United States, 92868
Contact: Site Public Contact    877-827-8839    ucstudy@uci.edu   
Principal Investigator: Fa-Chyi Lee         
Kaiser Permanente - Panorama City Recruiting
Panorama City, California, United States, 91402
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente-Riverside Recruiting
Riverside, California, United States, 92505
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Site Public Contact    916-734-3089      
Principal Investigator: May T. Cho         
Kaiser Permanente-San Diego Mission Recruiting
San Diego, California, United States, 92108
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente-San Diego Zion Recruiting
San Diego, California, United States, 92120
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
Kaiser Permanente-San Marcos Recruiting
San Marcos, California, United States, 92078
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
John Muir Medical Center-Walnut Creek Active, not recruiting
Walnut Creek, California, United States, 94598
Kaiser Permanente-Woodland Hills Recruiting
Woodland Hills, California, United States, 91367
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Gary L. Buchschacher         
United States, Colorado
Rocky Mountain Cancer Centers-Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Site Public Contact    720-848-0650      
Principal Investigator: Alexis D. Leal         
Boulder Community Hospital Recruiting
Boulder, Colorado, United States, 80301
Contact: Site Public Contact    303-777-2663    jbloomfield@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Boulder Recruiting
Boulder, Colorado, United States, 80304
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
UCHealth Memorial Hospital Central Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Site Public Contact    719-365-2406      
Principal Investigator: Alexis D. Leal         
Memorial Hospital North Recruiting
Colorado Springs, Colorado, United States, 80920
Contact: Site Public Contact    719-364-6700      
Principal Investigator: Alexis D. Leal         
Denver Health Medical Center Suspended
Denver, Colorado, United States, 80204
National Jewish Health-Main Campus Recruiting
Denver, Colorado, United States, 80206
Contact: Site Public Contact    877-225-5654    glicht@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Midtown Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
SCL Health Saint Joseph Hospital Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Rose Recruiting
Denver, Colorado, United States, 80220
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Mountain Blue Cancer Care Center - Swedish Recruiting
Englewood, Colorado, United States, 80113
Contact: Site Public Contact    303-777-2663    WSCR@westernstatesncorp.org   
Principal Investigator: Keren Sturtz         
Swedish Medical Center Recruiting
Englewood, Colorado, United States, 80113
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Site Public Contact    970-297-6150      
Principal Investigator: Alexis D. Leal         
National Jewish Health-Western Hematology Oncology Suspended
Golden, Colorado, United States, 80401
North Colorado Medical Center Recruiting
Greeley, Colorado, United States, 80631
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Littleton Recruiting
Littleton, Colorado, United States, 80120
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Sky Ridge Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
McKee Medical Center Recruiting
Loveland, Colorado, United States, 80539
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
National Jewish Health-Northern Hematology Oncology Recruiting
Thornton, Colorado, United States, 80260
Contact: Site Public Contact    303-777-2663    glicht@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
SCL Health Lutheran Medical Center Recruiting
Wheat Ridge, Colorado, United States, 80033
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
United States, Connecticut
Danbury Hospital Recruiting
Danbury, Connecticut, United States, 06810
Contact: Site Public Contact    203-739-8074      
Principal Investigator: Wenli GaO         
Hartford Hospital Recruiting
Hartford, Connecticut, United States, 06102
Contact: Site Public Contact    860-545-5363      
Principal Investigator: Gerard Fumo         
Midstate Medical Center Recruiting
Meriden, Connecticut, United States, 06451
Contact: Site Public Contact    866-662-5678      
Principal Investigator: Gerard Fumo         
The Hospital of Central Connecticut Recruiting
New Britain, Connecticut, United States, 06050
Contact: Site Public Contact    860-224-5660      
Principal Investigator: Gerard Fumo         
William Backus Hospital Recruiting
Norwich, Connecticut, United States, 06360
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Gerard Fumo         
United States, Delaware
Helen F Graham Cancer Center Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Medical Oncology Hematology Consultants PA Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
United States, District of Columbia
Kaiser Permanente-Capitol Hill Medical Center Recruiting
Washington, District of Columbia, United States, 20002
Contact: Site Public Contact    301-548-5743      
Principal Investigator: Leon C. Hwang         
United States, Florida
Broward Health Medical Center Recruiting
Fort Lauderdale, Florida, United States, 33316
Contact: Site Public Contact    954-355-5346      
Principal Investigator: Jorge Hurtado-cordovi         
Regional Cancer Center-Lee Memorial Health System Recruiting
Fort Myers, Florida, United States, 33905
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Paul M. Bloomston         
University of Florida Health Science Center - Gainesville Recruiting
Gainesville, Florida, United States, 32610
Contact: Site Public Contact    352-273-8010    cancer-center@ufl.edu   
Principal Investigator: Thomas J. George         
Baptist MD Anderson Cancer Center Suspended
Jacksonville, Florida, United States, 32207
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute Recruiting
Boise, Idaho, United States, 83712
Contact: Site Public Contact    208-381-2774    eslinget@slhs.org   
Principal Investigator: Dan S. Zuckerman         
Saint Alphonsus Cancer Care Center-Caldwell Recruiting
Caldwell, Idaho, United States, 83605
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Medical Center Recruiting
Coeur d'Alene, Idaho, United States, 83814
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute - Fruitland Recruiting
Fruitland, Idaho, United States, 83619
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Dan S. Zuckerman         
Saint Luke's Mountain States Tumor Institute - Meridian Recruiting
Meridian, Idaho, United States, 83642
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Dan S. Zuckerman         
Saint Alphonsus Medical Center-Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute - Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Dan S. Zuckerman         
Kootenai Cancer Center Recruiting
Post Falls, Idaho, United States, 83854
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Cancer Clinic Recruiting
Sandpoint, Idaho, United States, 83864
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute-Twin Falls Recruiting
Twin Falls, Idaho, United States, 83301
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Dan S. Zuckerman         
United States, Illinois
Illinois CancerCare-Bloomington Recruiting
Bloomington, Illinois, United States, 61704
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Canton Recruiting
Canton, Illinois, United States, 61520
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Carthage Recruiting
Carthage, Illinois, United States, 62321
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Centralia Oncology Clinic Recruiting
Centralia, Illinois, United States, 62801
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-942-5498    clinical_trials@rush.edu   
Principal Investigator: William T. Leslie         
University of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-355-3046      
Principal Investigator: Neeta K. Venepalli         
Carle on Vermilion Recruiting
Danville, Illinois, United States, 61832
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Suparna Mantha         
Cancer Care Specialists of Illinois - Decatur Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Dixon Recruiting
Dixon, Illinois, United States, 61021
Contact: Site Public Contact    815-285-7800      
Principal Investigator: Bryan A. Faller         
Carle Physician Group-Effingham Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Suparna Mantha         
Crossroads Cancer Center Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Eureka Recruiting
Eureka, Illinois, United States, 61530
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
NorthShore University HealthSystem-Evanston Hospital Recruiting
Evanston, Illinois, United States, 60201
Contact: Site Public Contact    847-570-2109      
Principal Investigator: Robert d. Marsh         
Illinois CancerCare-Galesburg Recruiting
Galesburg, Illinois, United States, 61401
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
NorthShore University HealthSystem-Glenbrook Hospital Recruiting
Glenview, Illinois, United States, 60026
Contact: Site Public Contact    847-570-2109      
Principal Investigator: Robert d. Marsh         
NorthShore University HealthSystem-Highland Park Hospital Recruiting
Highland Park, Illinois, United States, 60035
Contact: Site Public Contact    847-570-2109      
Principal Investigator: Robert d. Marsh         
Illinois CancerCare-Kewanee Clinic Recruiting
Kewanee, Illinois, United States, 61443
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Macomb Recruiting
Macomb, Illinois, United States, 61455
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Carle Physician Group-Mattoon/Charleston Recruiting
Mattoon, Illinois, United States, 61938
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Suparna Mantha         
Loyola University Medical Center Recruiting
Maywood, Illinois, United States, 60153
Contact: Site Public Contact    708-226-4357      
Principal Investigator: Asha R. Dhanarajan         
Illinois CancerCare-Ottawa Clinic Recruiting
Ottawa, Illinois, United States, 61350
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Pekin Recruiting
Pekin, Illinois, United States, 61554
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Peru Recruiting
Peru, Illinois, United States, 61354
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Princeton Recruiting
Princeton, Illinois, United States, 61356
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Southern Illinois University School of Medicine Recruiting
Springfield, Illinois, United States, 62702
Contact: Site Public Contact    217-545-7929      
Principal Investigator: Bryan A. Faller         
Springfield Clinic Recruiting
Springfield, Illinois, United States, 62702
Contact: Site Public Contact    800-444-7541      
Principal Investigator: Bryan A. Faller         
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Suparna Mantha         
United States, Indiana
Indiana University/Melvin and Bren Simon Cancer Center Active, not recruiting
Indianapolis, Indiana, United States, 46202
Community Cancer Center East Recruiting
Indianapolis, Indiana, United States, 46219
Contact: Site Public Contact    317-497-2823    lcheri@ecommunity.com   
Principal Investigator: Mary L. Mayer         
Community Cancer Center South Recruiting
Indianapolis, Indiana, United States, 46227
Contact: Site Public Contact    317-497-2823    lcheri@ecommunity.com   
Principal Investigator: Mary L. Mayer         
Franciscan Health Indianapolis Recruiting
Indianapolis, Indiana, United States, 46237
Contact: Site Public Contact    317-528-7060      
Principal Investigator: Meghana Raghavendra         
Community Cancer Center North Recruiting
Indianapolis, Indiana, United States, 46256
Contact: Site Public Contact    317-497-2823    lcheri@ecommunity.com   
Principal Investigator: Mary L. Mayer         
Community Howard Regional Health Recruiting
Kokomo, Indiana, United States, 46904
Contact: Site Public Contact    765-453-8571    oncology@communityhoward.org   
Principal Investigator: Mary L. Mayer         
Woodland Cancer Care Center Recruiting
Michigan City, Indiana, United States, 46360
Contact: Site Public Contact    219-861-5800    sally.arnett@franciscanalliance.org   
Principal Investigator: Meghana Raghavendra         
Franciscan Health Mooresville Recruiting
Mooresville, Indiana, United States, 46158
Contact: Site Public Contact    317-834-3603      
Principal Investigator: Meghana Raghavendra         
Union Hospital Recruiting
Terre Haute, Indiana, United States, 47804
Contact: Site Public Contact    812-238-7394      
Principal Investigator: Meghana Raghavendra         
United States, Iowa
Mary Greeley Medical Center Recruiting
Ames, Iowa, United States, 50010
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
McFarland Clinic PC - Ames Recruiting
Ames, Iowa, United States, 50010
Contact: Site Public Contact    515-239-4734    ksoder@mcfarlandclinic.com   
Principal Investigator: Debra M. Prow         
University of Iowa Healthcare Cancer Services Quad Cities Recruiting
Bettendorf, Iowa, United States, 52722
Contact: Site Public Contact    563-355-7733    kedaprile@rccqc.com   
Principal Investigator: Saima Sharif         
McFarland Clinic PC-Boone Recruiting
Boone, Iowa, United States, 50036
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
Mercy Hospital Recruiting
Cedar Rapids, Iowa, United States, 52403
Contact: Site Public Contact    319-365-4673      
Principal Investigator: Deborah W. Wilbur         
Oncology Associates at Mercy Medical Center Recruiting
Cedar Rapids, Iowa, United States, 52403
Contact: Site Public Contact    319-363-2690      
Principal Investigator: Deborah W. Wilbur         
Medical Oncology and Hematology Associates-West Des Moines Recruiting
Clive, Iowa, United States, 50325
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Cancer Center-West Lakes Recruiting
Clive, Iowa, United States, 50325
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Medical Oncology and Hematology Associates-Des Moines Recruiting
Des Moines, Iowa, United States, 50309
Contact: Site Public Contact    515-282-2921      
Principal Investigator: Robert J. Behrens         
Broadlawns Medical Center Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    515-282-2200      
Principal Investigator: Robert J. Behrens         
Medical Oncology and Hematology Associates-Laurel Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Medical Center - Des Moines Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
McFarland Clinic PC-Trinity Cancer Center Recruiting
Fort Dodge, Iowa, United States, 50501
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
Trinity Regional Medical Center Recruiting
Fort Dodge, Iowa, United States, 50501
Contact: Site Public Contact    515-574-8302      
Principal Investigator: Robert J. Behrens         
University of Iowa/Holden Comprehensive Cancer Center Recruiting
Iowa City, Iowa, United States, 52242
Contact: Site Public Contact    800-237-1225      
Principal Investigator: Saima Sharif         
McFarland Clinic PC-Jefferson Recruiting
Jefferson, Iowa, United States, 50129
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
McFarland Clinic PC-Marshalltown Recruiting
Marshalltown, Iowa, United States, 50158
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
Mercy Medical Center-West Lakes Recruiting
West Des Moines, Iowa, United States, 50266
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Kansas
Hays Medical Center Recruiting
Hays, Kansas, United States, 67601
Contact: Site Public Contact    785-623-5774      
Principal Investigator: Anwaar Saeed         
Lawrence Memorial Hospital Recruiting
Lawrence, Kansas, United States, 66044
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Pavan S. Reddy         
Olathe Medical Center Recruiting
Olathe, Kansas, United States, 66061
Contact: Site Public Contact    913-791-3500    Jeni.wakefield@olathehealth.org   
Principal Investigator: Anwaar Saeed         
Salina Regional Health Center Recruiting
Salina, Kansas, United States, 67401
Contact: Site Public Contact    785-452-7038    kkavoura@srhc.com   
Principal Investigator: Anwaar Saeed         
Saint Francis Hospital and Medical Center - Topeka Recruiting
Topeka, Kansas, United States, 66606
Contact: Site Public Contact    785-295-8000      
Principal Investigator: Anwaar Saeed         
University of Kansas Hospital-Westwood Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Anwaar Saeed         
Cancer Center of Kansas-Wichita Medical Arts Tower Recruiting
Wichita, Kansas, United States, 67208
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Pavan S. Reddy         
Cancer Center of Kansas - Wichita Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Pavan S. Reddy         
United States, Kentucky
Flaget Memorial Hospital Recruiting
Bardstown, Kentucky, United States, 40004
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Baptist Health Lexington Recruiting
Lexington, Kentucky, United States, 40503
Contact: Site Public Contact    859-260-6425      
Principal Investigator: Lee G. Hicks         
Saint Joseph Hospital East Recruiting
Lexington, Kentucky, United States, 40509
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
University of Kentucky/Markey Cancer Center Recruiting
Lexington, Kentucky, United States, 40536
Contact: Site Public Contact    859-257-3379      
Principal Investigator: Zhonglin Hao         
Norton Hospital Pavilion and Medical Campus Recruiting
Louisville, Kentucky, United States, 40202
Contact: Site Public Contact    502-629-2500      
Principal Investigator: Michael F. Driscoll         
Norton Audubon Hospital and Medical Campus Recruiting
Louisville, Kentucky, United States, 40217
Contact: Site Public Contact    502-629-3465      
Principal Investigator: Michael F. Driscoll         
Norton Brownsboro Hospital and Medical Campus Recruiting
Louisville, Kentucky, United States, 40241
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Michael F. Driscoll         
United States, Louisiana
Ochsner Medical Center Kenner Recruiting
Kenner, Louisiana, United States, 70065
Contact: Site Public Contact    504-464-8314    cris.molina@ochsner.org   
Principal Investigator: Suma P. Satti         
Ochsner Medical Center Jefferson Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Site Public Contact    504-703-8712    Gregory.Johnstone@ochsner.org   
Principal Investigator: Suma P. Satti         
United States, Maine
Harold Alfond Center for Cancer Care Recruiting
Augusta, Maine, United States, 04330
Contact: Site Public Contact    207-626-4855      
Principal Investigator: Peter Rubin         
Eastern Maine Medical Center Recruiting
Bangor, Maine, United States, 04401
Contact: Site Public Contact    207-973-4274      
Principal Investigator: Sarah J. Sinclair         
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford Recruiting
Biddeford, Maine, United States, 04005
Contact: Site Public Contact       LLemire@mmc.org   
Principal Investigator: Peter Rubin         
Lafayette Family Cancer Center-EMMC Recruiting
Brewer, Maine, United States, 04412
Contact: Site Public Contact    800-987-3005      
Principal Investigator: Sarah J. Sinclair         
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford Recruiting
Sanford, Maine, United States, 04073
Contact: Site Public Contact       LLemire@mmc.org   
Principal Investigator: Peter Rubin         
Maine Medical Partners - South Portland Recruiting
South Portland, Maine, United States, 04106
Contact: Site Public Contact    207-396-8670    ClinicalResearch@mmc.org   
Principal Investigator: Peter Rubin         
United States, Maryland
Kaiser Permanente-Woodlawn Medical Center Recruiting
Baltimore, Maryland, United States, 21244
Contact: Site Public Contact    301-816-7218      
Principal Investigator: Leon C. Hwang         
University of Maryland Shore Medical Center at Easton Recruiting
Easton, Maryland, United States, 21601
Contact: Site Public Contact    410-822-1000    Christina.weisenborn@umm.edu   
Principal Investigator: Mary S. De Shields         
Kaiser Permanente-Gaithersburg Medical Center Recruiting
Gaithersburg, Maryland, United States, 20879
Contact: Site Public Contact    301-816-7218      
Principal Investigator: Leon C. Hwang         
Kaiser Permanente - Largo Medical Center Recruiting
Largo, Maryland, United States, 20774
Contact: Site Public Contact    301-816-7446      
Principal Investigator: Leon C. Hwang         
United States, Massachusetts
Lowell General Hospital Recruiting
Lowell, Massachusetts, United States, 01854
Contact: Site Public Contact    978-788-7084    ghincks@lowellgeneral.org   
Principal Investigator: Murat A. Anamur         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
McLaren Cancer Institute-Bay City Recruiting
Bay City, Michigan, United States, 48706
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
McLaren Cancer Institute-Bloomfield Recruiting
Bloomfield, Michigan, United States, 48302
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
IHA Hematology Oncology Consultants-Brighton Recruiting
Brighton, Michigan, United States, 48114
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Joseph Mercy Brighton Recruiting
Brighton, Michigan, United States, 48114
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Henry Ford Cancer Institute-Downriver Recruiting
Brownstown, Michigan, United States, 48183
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Haythem Y. Ali         
IHA Hematology Oncology Consultants-Canton Recruiting
Canton, Michigan, United States, 48188
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Joseph Mercy Canton Recruiting
Canton, Michigan, United States, 48188
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
IHA Hematology Oncology Consultants-Chelsea Recruiting
Chelsea, Michigan, United States, 48118
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Joseph Mercy Chelsea Recruiting
Chelsea, Michigan, United States, 48118
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Hematology Oncology Consultants-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
McLaren Cancer Institute-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Newland Medical Associates-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Henry Ford Macomb Hospital-Clinton Township Recruiting
Clinton Township, Michigan, United States, 48038
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Haythem Y. Ali         
Henry Ford Medical Center-Fairlane Recruiting
Dearborn, Michigan, United States, 48126
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Haythem Y. Ali         
Wayne State University/Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Haythem Y. Ali         
Weisberg Cancer Treatment Center Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
McLaren Cancer Institute-Flint Recruiting
Flint, Michigan, United States, 48532
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Singh and Arora Hematology Oncology PC Recruiting
Flint, Michigan, United States, 48532
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Spectrum Health at Butterworth Campus Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Allegiance Health Recruiting
Jackson, Michigan, United States, 49201
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Haythem Y. Ali         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
McLaren-Greater Lansing Recruiting
Lansing, Michigan, United States, 48910
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
McLaren Cancer Institute-Lapeer Region Recruiting
Lapeer, Michigan, United States, 48446
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Hope Cancer Clinic Recruiting
Livonia, Michigan, United States, 48154
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
McLaren Cancer Institute-Macomb Recruiting
Mount Clemens, Michigan, United States, 48043
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Henry Ford Medical Center-Columbus Recruiting
Novi, Michigan, United States, 48377
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Haythem Y. Ali         
McLaren Cancer Institute-Northern Michigan Recruiting
Petoskey, Michigan, United States, 49770
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Newland Medical Associates-Pontiac Recruiting
Pontiac, Michigan, United States, 48341
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Joseph Mercy Oakland Recruiting
Pontiac, Michigan, United States, 48341
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
McLaren-Port Huron Recruiting
Port Huron, Michigan, United States, 48060
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Anteneh A. Tesfaye         
Ascension Saint Mary's Hospital Recruiting
Saginaw, Michigan, United States, 48601
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Oncology Hematology Associates of Saginaw Valley PC Recruiting
Saginaw, Michigan, United States, 48604
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Ascension Saint Joseph Hospital Recruiting
Tawas City, Michigan, United States, 48764
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Munson Medical Center Recruiting
Traverse City, Michigan, United States, 49684
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Henry Ford West Bloomfield Hospital Recruiting
West Bloomfield, Michigan, United States, 48322
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Haythem Y. Ali         
Saint Mary's Oncology/Hematology Associates of West Branch Recruiting
West Branch, Michigan, United States, 48661
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
IHA Hematology Oncology Consultants-Ann Arbor Recruiting
Ypsilanti, Michigan, United States, 48197
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
United States, Minnesota
Sanford Joe Lueken Cancer Center Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Site Public Contact    218-333-5000    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Essentia Health - Deer River Clinic Recruiting
Deer River, Minnesota, United States, 56636
Contact: Site Public Contact    218-786-3308    CancerTrials@EssentiaHealth.org   
Principal Investigator: Bret E. Friday         
Essentia Health Cancer Center Recruiting
Duluth, Minnesota, United States, 55805
Contact: Site Public Contact    218-786-3308    CancerTrials@EssentiaHealth.org   
Principal Investigator: Bret E. Friday         
Essentia Health Hibbing Clinic Recruiting
Hibbing, Minnesota, United States, 55746
Contact: Site Public Contact    218-786-3308    CancerTrials@EssentiaHealth.org   
Principal Investigator: Bret E. Friday         
Health Partners Inc Recruiting
Minneapolis, Minnesota, United States, 55454
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Richard T. Zera         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Richard T. Zera         
Essentia Health Virginia Clinic Recruiting
Virginia, Minnesota, United States, 55792
Contact: Site Public Contact    218-786-3308    CancerTrials@EssentiaHealth.org   
Principal Investigator: Bret E. Friday         
United States, Mississippi
Baptist Cancer Center-Grenada Recruiting
Grenada, Mississippi, United States, 38901
Contact: Site Public Contact    901-226-1366    BCCclintrials@bmhcc.org   
Principal Investigator: Shailesh R. Satpute         
Baptist Memorial Hospital and Cancer Center-Union County Recruiting
New Albany, Mississippi, United States, 38652
Contact: Site Public Contact    901-226-1366    BCCclintrials@bmhcc.org   
Principal Investigator: Shailesh R. Satpute         
Baptist Memorial Hospital and Cancer Center-Oxford Recruiting
Oxford, Mississippi, United States, 38655
Contact: Site Public Contact    901-226-1366    BCCclintrials@bmhcc.org   
Principal Investigator: Shailesh R. Satpute         
Baptist Memorial Hospital and Cancer Center-Desoto Recruiting
Southhaven, Mississippi, United States, 38671
Contact: Site Public Contact    901-226-1366    BCCclintrials@bmhcc.org   
Principal Investigator: Shailesh R. Satpute         
United States, Missouri
Saint Louis Cancer and Breast Institute-Ballwin Recruiting
Ballwin, Missouri, United States, 63011
Contact: Site Public Contact    314-251-7058      
Principal Investigator: Jay W. Carlson         
Saint Francis Medical Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact    573-334-2230    sfmc@sfmc.net   
Principal Investigator: Bryan A. Faller         
Freeman Health System Suspended
Joplin, Missouri, United States, 64804
Mercy Hospital Joplin Recruiting
Joplin, Missouri, United States, 64804
Contact: Site Public Contact    417-556-3074    esmeralda.carrillo@mercy.net   
Principal Investigator: Jay W. Carlson         
Truman Medical Center Recruiting
Kansas City, Missouri, United States, 64108
Contact: Site Public Contact    816-404-4375      
Principal Investigator: Anwaar Saeed         
Saint Louis Cancer and Breast Institute-South City Recruiting
Saint Louis, Missouri, United States, 63109
Contact: Site Public Contact    314-353-1870      
Principal Investigator: Jay W. Carlson         
Mercy Hospital Saint Louis Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Site Public Contact    314-251-7066      
Principal Investigator: Jay W. Carlson         
United States, Montana
Community Hospital of Anaconda Suspended
Anaconda, Montana, United States, 59711
Billings Clinic Cancer Center Recruiting
Billings, Montana, United States, 59101
Contact: Site Public Contact    800-996-2663    research@billingsclinic.org   
Principal Investigator: John M. Schallenkamp         
Bozeman Deaconess Hospital Recruiting
Bozeman, Montana, United States, 59715
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Great Falls Clinic Suspended
Great Falls, Montana, United States, 59405
Saint Peter's Community Hospital Suspended
Helena, Montana, United States, 59601
Kalispell Regional Medical Center Recruiting
Kalispell, Montana, United States, 59901
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Community Medical Hospital Recruiting
Missoula, Montana, United States, 59804
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
United States, Nebraska
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Site Public Contact    402-354-5144      
Principal Investigator: Timothy Huyck         
United States, Nevada
OptumCare Cancer Care at Seven Hills Recruiting
Henderson, Nevada, United States, 89052
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at Oakey Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at MountainView Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at Fort Apache Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Renown Regional Medical Center Recruiting
Reno, Nevada, United States, 89502
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
United States, New Hampshire
Dartmouth Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Site Public Contact    800-639-6918    cancer.research.nurse@dartmouth.edu   
Principal Investigator: Kathryn C. Hourdequin         
Norris Cotton Cancer Center-Manchester Recruiting
Manchester, New Hampshire, United States, 03102
Contact: Site Public Contact    603-629-1828      
Principal Investigator: Kathryn C. Hourdequin         
Norris Cotton Cancer Center-Nashua Recruiting
Nashua, New Hampshire, United States, 03063
Contact: Site Public Contact    603-577-4282    Laura.A.Menken@hitchcock.org   
Principal Investigator: Kathryn C. Hourdequin         
United States, New Jersey
The Cancer Institute of New Jersey Hamilton Recruiting
Hamilton, New Jersey, United States, 08690
Contact: Site Public Contact    609-631-6946      
Principal Investigator: Howard S. Hochster         
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Site Public Contact    732-235-8675      
Principal Investigator: Howard S. Hochster         
The Valley Hospital-Luckow Pavilion Recruiting
Paramus, New Jersey, United States, 07652
Contact: Site Public Contact    201-634-5792      
Principal Investigator: Kevin C. Wood         
Valley Hospital Recruiting
Ridgewood, New Jersey, United States, 07450
Contact: Site Public Contact    201-634-5792    cparish@valleyhealth.com   
Principal Investigator: Kevin C. Wood         
Robert Wood Johnson University Hospital Somerset Recruiting
Somerville, New Jersey, United States, 08876
Contact: Site Public Contact    908-685-2481      
Principal Investigator: Beiqing Pan         
United States, New Mexico
University of New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Site Public Contact    505-925-0366    LByatt@nmcca.org   
Principal Investigator: Vi K. Chiu         
Memorial Medical Center - Las Cruces Recruiting
Las Cruces, New Mexico, United States, 88011
Contact: Site Public Contact    575-556-6545    Kim.Hoffman@lpnt.net   
Principal Investigator: Vi K. Chiu         
United States, New York
Roswell Park Cancer Institute Suspended
Buffalo, New York, United States, 14263
Arnot Ogden Medical Center/Falck Cancer Center Recruiting
Elmira, New York, United States, 14905
Contact: Site Public Contact    607-271-7000      
Principal Investigator: Serge Dauphin         
Northwell Health/Center for Advanced Medicine Active, not recruiting
Lake Success, New York, United States, 11042
Laura and Isaac Perlmutter Cancer Center at NYU Langone Recruiting
New York, New York, United States, 10016
Contact: Site Public Contact    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: Deirdre J. Cohen         
University of Rochester Suspended
Rochester, New York, United States, 14642
Dickstein Cancer Treatment Center Recruiting
White Plains, New York, United States, 10601
Contact: Site Public Contact    914-849-7582    mcortese@wphospital.org   
Principal Investigator: Julie A. Monroe         
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Site Public Contact    877-668-0683    cancerclinicaltrials@med.unc.edu   
Principal Investigator: Hanna K. Sanoff         
Margaret R Pardee Memorial Hospital Recruiting
Hendersonville, North Carolina, United States, 28791
Contact: Site Public Contact    828-696-4716    karen.morris@unchealth.unc.edu   
Principal Investigator: James E. Radford         
Vidant Oncology-Kenansville Recruiting
Kenansville, North Carolina, United States, 28349
Contact: Site Public Contact    252-559-2201    Carla.Zimmerman@vidanthealth.com   
Principal Investigator: Misbah U. Qadir         
Vidant Oncology-Kinston Recruiting
Kinston, North Carolina, United States, 28501
Contact: Site Public Contact    252-559-2201    Carla.Zimmerman@vidanthealth.com   
Principal Investigator: Misbah U. Qadir         
FirstHealth of the Carolinas-Moore Regional Hospital Recruiting
Pinehurst, North Carolina, United States, 28374
Contact: Site Public Contact    910-715-3500    jcwilliams@firsthealth.org   
Principal Investigator: Charles S. Kuzma         
Vidant Oncology-Richlands Recruiting
Richlands, North Carolina, United States, 28574
Contact: Site Public Contact    252-559-2201    Carla.Zimmerman@vidanthealth.com   
Principal Investigator: Misbah U. Qadir         
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Site Public Contact    336-713-6771      
Principal Investigator: Caio Max S. Rocha Lima         
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Sanford Broadway Medical Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Sanford Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact    701-234-6161    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Altru Cancer Center Recruiting
Grand Forks, North Dakota, United States, 58201
Contact: Site Public Contact    701-780-6520      
Principal Investigator: Grant R. Seeger         
United States, Ohio
Cleveland Clinic Akron General Recruiting
Akron, Ohio, United States, 44307
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Esther H. Rehmus         
Strecker Cancer Center-Belpre Recruiting
Belpre, Ohio, United States, 45714
Contact: Site Public Contact    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Dayton Physicians LLC-Miami Valley South Recruiting
Centerville, Ohio, United States, 45459
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Miami Valley Hospital South Recruiting
Centerville, Ohio, United States, 45459
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: Site Public Contact    877-779-7585    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
University of Cincinnati/Barrett Cancer Center Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Site Public Contact    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Jordan Kharofa         
Cleveland Clinic Cancer Center/Fairview Hospital Recruiting
Cleveland, Ohio, United States, 44111
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Mark K. Kyei         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: John L. Hays         
Mount Carmel East Hospital Recruiting
Columbus, Ohio, United States, 43213
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Columbus Oncology and Hematology Associates Inc Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Mount Carmel Health Center West Recruiting
Columbus, Ohio, United States, 43222
Contact: Site Public Contact    614-234-5433    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Doctors Hospital Recruiting
Columbus, Ohio, United States, 43228
Contact: Site Public Contact    614-566-3275    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Miami Valley Hospital Recruiting
Dayton, Ohio, United States, 45409
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Delaware Health Center-Grady Cancer Center Recruiting
Delaware, Ohio, United States, 43015
Contact: Site Public Contact    740-615-0227    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Grady Memorial Hospital Recruiting
Delaware, Ohio, United States, 43015
Contact: Site Public Contact    740-615-2403    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Greater Dayton Cancer Center Recruiting
Kettering, Ohio, United States, 45409
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Fairfield Medical Center Recruiting
Lancaster, Ohio, United States, 43130
Contact: Site Public Contact    740-687-8863    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Mansfield Hospital Recruiting
Mansfield, Ohio, United States, 44903
Contact: Site Public Contact    419-526-8018    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Cleveland Clinic Cancer Center Mansfield Recruiting
Mansfield, Ohio, United States, 44906
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Mark K. Kyei         
Marietta Memorial Hospital Recruiting
Marietta, Ohio, United States, 45750
Contact: Site Public Contact    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Marion General Hospital Recruiting
Marion, Ohio, United States, 43302
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Hillcrest Hospital Cancer Center Recruiting
Mayfield Heights, Ohio, United States, 44124
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Mark K. Kyei         
Knox Community Hospital Recruiting
Mount Vernon, Ohio, United States, 43050
Contact: Site Public Contact    740-393-9000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Licking Memorial Hospital Recruiting
Newark, Ohio, United States, 43055
Contact: Site Public Contact    740-348-4000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Southern Ohio Medical Center Recruiting
Portsmouth, Ohio, United States, 45662
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
North Coast Cancer Care Recruiting
Sandusky, Ohio, United States, 44870
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Mark K. Kyei         
ProMedica Flower Hospital Recruiting
Sylvania, Ohio, United States, 43560
Contact: Site Public Contact    419-824-1842      
Principal Investigator: Feng Jiang         
South Pointe Hospital Recruiting
Warrensville Heights, Ohio, United States, 44122
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Mark K. Kyei         
University Pointe Recruiting
West Chester, Ohio, United States, 45069
Contact: Site Public Contact       clinicaltrials@ucphysicians.com   
Principal Investigator: Jordan Kharofa         
Saint Ann's Hospital Recruiting
Westerville, Ohio, United States, 43081
Contact: Site Public Contact    614-234-5433    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Genesis Healthcare System Cancer Care Center Recruiting
Zanesville, Ohio, United States, 43701
Contact: Site Public Contact    740-454-5232    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
United States, Oklahoma
Cancer Centers of Southwest Oklahoma Research Recruiting
Lawton, Oklahoma, United States, 73505
Contact: Site Public Contact    877-231-4440      
Principal Investigator: Susanna V. Ulahannan         
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Susanna V. Ulahannan         
Oklahoma Cancer Specialists and Research Institute-Tulsa Recruiting
Tulsa, Oklahoma, United States, 74146
Contact: Site Public Contact    918-505-3200      
Principal Investigator: Susanna V. Ulahannan         
United States, Oregon
Providence Oncology and Hematology Care Southeast Recruiting
Clackamas, Oregon, United States, 97015
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
Providence Newberg Medical Center Recruiting
Newberg, Oregon, United States, 97132
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
Providence Saint Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
United States, Pennsylvania
Lehigh Valley Hospital-Cedar Crest Recruiting
Allentown, Pennsylvania, United States, 18103
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Luke's University Hospital-Bethlehem Campus Recruiting
Bethlehem, Pennsylvania, United States, 18015
Contact: Site Public Contact    484-503-4151      
Principal Investigator: Sheikh Asim Ali         
Lehigh Valley Hospital - Muhlenberg Recruiting
Bethlehem, Pennsylvania, United States, 18017
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Vincent Hospital Recruiting
Erie, Pennsylvania, United States, 16544
Contact: Site Public Contact    814-452-5000      
Principal Investigator: Amjad Jalil         
UPMC Pinnacle Cancer Center/Community Osteopathic Campus Recruiting
Harrisburg, Pennsylvania, United States, 17109
Contact: Site Public Contact    717-724-6765    klitchfield@PINNACLEHEALTH.org   
Principal Investigator: Nathan Bahary         
Jefferson Hospital Recruiting
Jefferson Hills, Pennsylvania, United States, 15025
Contact: Site Public Contact    412-359-3043    ddefazio@wpahs.org   
Principal Investigator: Amjad Jalil         
Forbes Hospital Recruiting
Monroeville, Pennsylvania, United States, 15146
Contact: Site Public Contact    412-858-7746      
Principal Investigator: Amjad Jalil         
Allegheny Valley Hospital Recruiting
Natrona Heights, Pennsylvania, United States, 15065
Contact: Site Public Contact    724-226-7380      
Principal Investigator: Amjad Jalil         
Allegheny General Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15212
Contact: Site Public Contact    877-284-2000      
Principal Investigator: Amjad Jalil         
West Penn Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Site Public Contact    412-578-5000      
Principal Investigator: Amjad Jalil         
University of Pittsburgh Cancer Institute (UPCI) Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Site Public Contact    412-647-8073      
Principal Investigator: Nathan Bahary         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Site Public Contact    610-988-9323      
Principal Investigator: Terrence P. Cescon         
Wexford Health and Wellness Pavilion Recruiting
Wexford, Pennsylvania, United States, 15090
Contact: Site Public Contact    412-359-3043    ddefazio@wpahs.org   
Principal Investigator: Amjad Jalil         
Abington Memorial Hospital-Asplundh Cancer Pavilion Active, not recruiting
Willow Grove, Pennsylvania, United States, 19090
United States, South Carolina
Beaufort Memorial Hospital Recruiting
Beaufort, South Carolina, United States, 29902
Contact: Site Public Contact    843-522-7819    kwade@bmhsc.org   
Principal Investigator: William M. Newberry         
Prisma Health Cancer Institute - Easley Recruiting
Easley, South Carolina, United States, 29640
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Butternut Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Faris Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Eastside Recruiting
Greenville, South Carolina, United States, 29615
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Greer Recruiting
Greer, South Carolina, United States, 29650
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Seneca Recruiting
Seneca, South Carolina, United States, 29672
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Spartanburg Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Site Public Contact    864-560-6104    kmertz-rivera@gibbscc.org   
Principal Investigator: Roberto Ferro         
Prisma Health Cancer Institute - Spartanburg Recruiting
Spartanburg, South Carolina, United States, 29307
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
United States, South Dakota
Sanford Cancer Center Oncology Clinic Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Site Public Contact    605-312-3320    OncologyClinicTrialsSF@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Avera Cancer Institute Recruiting
Sioux Falls, South Dakota, United States, 57105
Contact: Site Public Contact    888-634-7268    oncregulatory@avera.org   
Principal Investigator: Benjamin M. Solomon         
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Site Public Contact    605-312-3320    OncologyClinicalTrialsSF@SanfordHealth.org   
Principal Investigator: Preston D. Steen         
United States, Tennessee
Wellmont Bristol Regional Medical Center Recruiting
Bristol, Tennessee, United States, 37620
Contact: Site Public Contact    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Baptist Memorial Hospital and Cancer Center-Collierville Recruiting
Collierville, Tennessee, United States, 38017
Contact: Site Public Contact    901-226-1366    BCCclintrials@bmhcc.org   
Principal Investigator: Shailesh R. Satpute         
Cookeville Regional Medical Center Recruiting
Cookeville, Tennessee, United States, 38501
Contact: Site Public Contact    931-783-2714      
Principal Investigator: Thomas J. Summers         
Wellmont Medical Associates Oncology and Hematology-Johnson City Suspended
Johnson City, Tennessee, United States, 37604
Regional Cancer Center at Indian Path Community Hospital Recruiting
Kingsport, Tennessee, United States, 37660
Contact: Site Public Contact    423-578-8538    Justin.reynolds@balladhealth.org   
Principal Investigator: Asheesh Shipstone         
Wellmont Holston Valley Hospital and Medical Center Recruiting
Kingsport, Tennessee, United States, 37660
Contact: Site Public Contact    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Baptist Memorial Hospital and Cancer Center-Memphis Recruiting
Memphis, Tennessee, United States, 38120
Contact: Site Public Contact    901-226-1366    BCCclintrials@bmhcc.org   
Principal Investigator: Shailesh R. Satpute         
United States, Texas
Baptist Hospitals of Southeast Texas Cancer Center Recruiting
Beaumont, Texas, United States, 77701
Contact: Site Public Contact    409-212-5956      
Principal Investigator: Ernest Hymel         
Parkland Memorial Hospital Not yet recruiting
Dallas, Texas, United States, 75235
Contact: Site Public Contact    214-590-5582    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Syed M. Kazmi         
UT Southwestern/Simmons Cancer Center-Dallas Not yet recruiting
Dallas, Texas, United States, 75390
Contact: Site Public Contact    214-648-7097    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Syed M. Kazmi         
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Site Public Contact    877-632-6789    askmdanderson@mdanderson.org   
Principal Investigator: Michael J. Overman         
The Methodist Hospital System Suspended
Houston, Texas, United States, 77030
Baptist Regional Cancer Network-Cancer Center of Southeast Texas Recruiting
Port Arthur, Texas, United States, 77642
Contact: Site Public Contact    409-729-8088      
Principal Investigator: Ernest Hymel         
United States, Utah
Huntsman Cancer Institute/University of Utah Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Site Public Contact    888-424-2100    cancerinfo@hci.utah.edu   
Principal Investigator: John R. Weis         
United States, Vermont
Norris Cotton Cancer Center-North Recruiting
Saint Johnsbury, Vermont, United States, 05819
Contact: Site Public Contact    802-473-4100      
Principal Investigator: Kathryn C. Hourdequin         
United States, Virginia
Wellmont Medical Associates-Bristol Recruiting
Bristol, Virginia, United States, 24201
Contact: Site Public Contact    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Kaiser Permanente-Burke Medical Center Recruiting
Burke, Virginia, United States, 22015
Contact: Site Public Contact       Diane.Fisher@nsmtp.kp.org   
Principal Investigator: Leon C. Hwang         
Augusta Health Center for Cancer and Blood Disorders Recruiting
Fishersville, Virginia, United States, 22939
Contact: Site Public Contact    540-332-5960      
Principal Investigator: Kelvin B. Raybon         
Centra Lynchburg Hematology-Oncology Clinic Inc Recruiting
Lynchburg, Virginia, United States, 24501
Contact: Site Public Contact    434-200-5925    Kevin.Patel@centrahealth.com   
Principal Investigator: Khalid Matin         
Southwest VA Regional Cancer Center Recruiting
Norton, Virginia, United States, 24273
Contact: Site Public Contact    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Virginia Commonwealth University/Massey Cancer Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Site Public Contact    804-628-1914    klcampbell@vcu.edu   
Principal Investigator: Khalid Matin         
VCU Community Memorial Health Center Recruiting
South Hill, Virginia, United States, 23970
Contact: Site Public Contact    434-774-2442    sherman.baker@vcuhealth.org   
Principal Investigator: Khalid Matin         
United States, Washington
Swedish Cancer Institute-Issaquah Recruiting
Issaquah, Washington, United States, 98029
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Dan S. Zuckerman         
Swedish Medical Center-First Hill Recruiting
Seattle, Washington, United States, 98122-4307
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Dan S. Zuckerman         
United States, West Virginia
West Virginia University Charleston Division Recruiting
Charleston, West Virginia, United States, 25304
Contact: Site Public Contact    304-388-9944      
Principal Investigator: Steven J. Jubelirer         
West Virginia University Healthcare Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Site Public Contact    304-293-7374    cancertrialsinfo@hsc.wvu.edu   
Principal Investigator: Sobha Kurian         
Camden Clark Medical Center Recruiting
Parkersburg, West Virginia, United States, 26101
Contact: Site Public Contact    304-293-7374    cancertrialsinfo@hsc.wvu.edu   
Principal Investigator: Sobha Kurian         
United States, Wisconsin
Langlade Hospital and Cancer Center Recruiting
Antigo, Wisconsin, United States, 54409
Contact: Site Public Contact    715-623-9869    Juli.Alford@aspirus.org   
Principal Investigator: Harish G. Ahuja         
Ascension Saint Elizabeth Hospital Recruiting
Appleton, Wisconsin, United States, 54915
Contact: Site Public Contact    920-831-8900    Dale.grimmer@ascension.org   
Principal Investigator: Kamal K. Abbi         
Duluth Clinic Ashland Recruiting
Ashland, Wisconsin, United States, 54806
Contact: Site Public Contact    218-786-3308    CancerTrials@EssentiaHealth.org   
Principal Investigator: Bret E. Friday         
Ascension Southeast Wisconsin Hospital - Elmbrook Campus Recruiting
Brookfield, Wisconsin, United States, 53045
Contact: Site Public Contact    414-635-6420    AWRI.Inquiry@Ascension.org   
Principal Investigator: Francis J. Cuevas         
Ascension Saint Francis - Reiman Cancer Center Recruiting
Franklin, Wisconsin, United States, 53132
Contact: Site Public Contact    414-635-6420    AWRI.Inquiry@Ascension.org   
Principal Investigator: Francis J. Cuevas         
Bellin Memorial Hospital Recruiting
Green Bay, Wisconsin, United States, 54301
Contact: Site Public Contact    920-435-8326      
Principal Investigator: Hassan I. Tahsildar         
Mercyhealth Hospital and Cancer Center - Janesville Recruiting
Janesville, Wisconsin, United States, 53548
Contact: Site Public Contact    888-396-3729      
Principal Investigator: Emily G. Robinson         
UW Cancer Center Johnson Creek Recruiting
Johnson Creek, Wisconsin, United States, 53038
Contact: Site Public Contact    920-699-3500    lynda.persico@uwmf.wisc.edu   
Principal Investigator: Daniel L. Mulkerin         
Gundersen Lutheran Medical Center Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Site Public Contact    608-775-2385    cancerctr@gundersenhealth.org   
Principal Investigator: Kurt Oettel         
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Site Public Contact    800-622-8922      
Principal Investigator: Daniel L. Mulkerin         
ProHealth D N Greenwald Center Recruiting
Mukwonago, Wisconsin, United States, 53149
Contact: Site Public Contact       research.institute@phci.org   
Principal Investigator: Timothy R. Wassenaar         
ProHealth Oconomowoc Memorial Hospital Recruiting
Oconomowoc, Wisconsin, United States, 53066
Contact: Site Public Contact    262-928-7878      
Principal Investigator: Timothy R. Wassenaar         
Ascension Mercy Hospital Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Site Public Contact    920-831-8900    Dale.grimmer@ascension.org   
Principal Investigator: Kamal K. Abbi         
Ascension All Saints Hospital Recruiting
Racine, Wisconsin, United States, 53405
Contact: Site Public Contact    414-635-6420    AWRI.Inquiry@Ascension.org   
Principal Investigator: Francis J. Cuevas         
ProHealth Waukesha Memorial Hospital Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Site Public Contact    262-928-7632      
Principal Investigator: Timothy R. Wassenaar         
UW Cancer Center at ProHealth Care Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Site Public Contact    262-928-5539    Chanda.miller@phci.org   
Principal Investigator: Timothy R. Wassenaar         
Aspirus Regional Cancer Center Recruiting
Wausau, Wisconsin, United States, 54401
Contact: Site Public Contact    877-405-6866      
Principal Investigator: Harish G. Ahuja         
Ascension Medical Group Southeast Wisconsin - Mayfair Road Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Site Public Contact    414-635-6420    AWRI.Inquiry@Ascension.org   
Principal Investigator: Francis J. Cuevas         
Aspirus UW Cancer Center Suspended
Wisconsin Rapids, Wisconsin, United States, 54494
United States, Wyoming
Cheyenne Regional Medical Center-West Recruiting
Cheyenne, Wyoming, United States, 82001
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Billings Clinic-Cody Suspended
Cody, Wyoming, United States, 82414
Sponsors and Collaborators
National Cancer Institute (NCI)
NRG Oncology
Investigators
Layout table for investigator information
Principal Investigator: James J Lee NRG Oncology

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02997228     History of Changes
Other Study ID Numbers: NCI-2016-01961
NCI-2016-01961 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NRG-GI004/S1610
NRG-GI004 ( Other Identifier: NRG Oncology )
NRG-GI004 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
First Posted: December 20, 2016    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Rectal Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Adenocarcinoma
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Carcinoma
Calcium, Dietary
Leucovorin
Folic Acid
Bevacizumab
Antineoplastic Agents, Immunological
Oxaliplatin
Fluorouracil
Atezolizumab
Endothelial Growth Factors
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Calcium
Levoleucovorin
Antineoplastic Agents